MedPath

Scleroderma: Functional Disability Between the Dominant and Contralateral Hand.

Not Applicable
Completed
Conditions
Scleroderma, Systemic
Interventions
Diagnostic Test: Measurement of joint amplitudes
Registration Number
NCT05171114
Lead Sponsor
University Hospital, Limoges
Brief Summary

Systemic sclerosis is an autoimmune disease in which the hand is responsible for 75% of the overall disability. Management is based on systemic treatments combined with kinesitherapy aimed at maintaining joint amplitudes, improving muscle strength and preventing stiffness. The aim of this study is to describe and compare the average spontaneous and attempted reduction range of motion limitations between the dominant and contralateral hand.

Detailed Description

Systemic sclerosis is an autoimmune disease in which the hand is responsible for 75% of the overall disability. In case of limitation, the level of skin fibrosis, Raynaud's syndrome and its complications, the search for painful joints with or without synovitis, and the presence of calcifications must therefore be assessed. Management is based on systemic treatments combined with kinesitherapy aimed at maintaining joint amplitudes, improving muscle strength and preventing stiffness. No study to date has compared the functionality of one hand to the other. The hypothesis is that there is a difference in range of motion limitations between the dominant hand and the contralateral hand.

Patients in the active file of the Internal Medicine A department of the Limoges University Hospital who meet the inclusion criteria will be offered the study by telephone. Patients wishing to participate will be given an appointment on a dedicated consultation slot. During this visit, Patients will be given an information note and their consent will be collected. The study examinations will be performed and the questionnaire completed. At the end of this visit, the study will be completed for the patient.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Group 1 :
  • Major patient
  • Diagnosis of diffuse or limited cutaneous systemic sclerosis according to the new ACR/EULAR criteria
  • Cochin hand score less than or equal to 16
  • Group 2 :
  • Major patient
  • Diagnosis of diffuse or limited cutaneous systemic sclerosis according to the new ACR/EULAR criteria
  • Cochin hand score greater than 16.
Exclusion Criteria
  • Overlap syndrome (Sharp or scleromyositis 2)
  • Patient with another autoimmune disease
  • History of surgery or trauma to the hand with proven functional sequelae
  • Presence of synovitis
  • Patient with Dupuytren's disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
moderate SclerodermaMeasurement of joint amplitudesPatients with Cochin hand score less than or equal to 16
severe SclerodermaMeasurement of joint amplitudesPatients with Cochin hand score greater than 16
Primary Outcome Measures
NameTimeMethod
Measurement of joint amplitudesat inclusion

Measurement of joint amplitudes by goniometry

Secondary Outcome Measures
NameTimeMethod
Number of subcutaneous calcificationsat inclusion
Number of digital ulcersat inclusion
Visual Analog Score for painat inclusion

Score varie from 0 (no pain) to 10 (worst pain possible)

Digital skin scoreat inclusion

Measure with modified Rodnan skin score. The value of this score varies from 0 (no cuntaneous sclerosis) to 51(severe cutaneous sclerosis).

Digital pressureat inclusion

use of Finger Systolic Blood Pressure Index (FBPI) proposed by Blaise et al.

number of painful jointsat inclusion

Trial Locations

Locations (1)

CHU de Limoges

🇫🇷

Limoges, France

© Copyright 2025. All Rights Reserved by MedPath